SIGA's Q3 Revenue Plunges 74% Amidst Product Sales Dip

TL;DR

**SIGA's Q3 revenue crash is a red flag, signaling volatile government contract timing despite strong year-to-date performance.**

AI Summary

SIGA Technologies Inc. reported a significant decline in revenue and a net loss for the three months ended September 30, 2025, with total revenues plummeting to $2.62 million from $10.01 million in the prior-year quarter, a 73.8% decrease. This was primarily driven by a sharp drop in product sales and supportive services revenue to $889,748 from $8.94 million. Consequently, the company posted a net loss of $6.37 million, or $0.09 per basic share, compared to a net income of $1.34 million, or $0.02 per basic share, in the same period of 2024. For the nine months ended September 30, 2025, total revenues increased to $90.78 million from $57.25 million, a 58.6% rise, largely due to product delivery revenue of $79.1 million. Net income for the nine-month period grew to $28.71 million, or $0.40 per basic share, up from $13.45 million, or $0.19 per basic share. Cash and cash equivalents increased by $16.56 million to $171.96 million as of September 30, 2025, from $155.40 million at the beginning of the period, despite a $43.03 million dividend payment. The company continues to manage its 19C BARDA Contract, which now contemplates up to approximately $630 million in payments, with recent increases of $14.3 million for manufacturing support and $13.2 million for pediatric formulation development.

Why It Matters

This filing reveals a concerning short-term revenue contraction for SIGA, primarily due to the timing of product deliveries, which could impact investor confidence and stock performance in the immediate future. While the nine-month figures show strong growth, the quarterly dip highlights the lumpy nature of government procurement contracts, a key competitive factor for SIGA's TPOXX. For employees, consistent contract execution is vital for job security and future growth initiatives. Customers, largely government entities, rely on timely deliveries, and any delays could affect national stockpiles. The broader market will watch how SIGA navigates these revenue fluctuations, especially given its niche in biodefense, a sector often influenced by geopolitical events and public health policy.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant quarter-over-quarter revenue decline of 73.8% in product sales and supportive services, from $8,942,875 in Q3 2024 to $889,748 in Q3 2025, leading to a net loss of $6,365,819. This volatility, while potentially offset by strong nine-month performance, indicates a reliance on large, infrequent contract deliveries, which introduces uncertainty for future quarterly results.

Analyst Insight

Investors should closely monitor SIGA's upcoming product delivery schedules and BARDA contract modifications, as the Q3 revenue drop appears to be a timing issue rather than a fundamental demand problem. Consider holding if you believe in the long-term stability of government biodefense contracts, but be prepared for continued quarterly volatility.

Financial Highlights

debt To Equity

0.14

revenue

$2.62M

operating Margin

-390.2%

total Assets

$231.60M

total Debt

$28.12M

net Income

($6.37M)

eps

($0.09)

gross Margin

-12.6%

cash Position

$171.96M

revenue Growth

-73.8%

Revenue Breakdown

Key Numbers

• $2.62M — Total Revenues (Q3 2025) (73.8% decrease from $10.01M in Q3 2024)
• $889,748 — Product Sales & Supportive Services (Q3 2025) (Significant drop from $8.94M in Q3 2024)
• ($6.37M) — Net Loss (Q3 2025) (Compared to $1.34M net income in Q3 2024)
• $90.78M — Total Revenues (9 Months 2025) (58.6% increase from $57.25M in 9 Months 2024)
• $28.71M — Net Income (9 Months 2025) (Increased from $13.45M in 9 Months 2024)
• $171.96M — Cash and Cash Equivalents (Sept 30, 2025) (Increased by $16.56M from Dec 31, 2024)
• $43.03M — Dividend Payment (9 Months 2025) (Cash used in financing activities)
• $630M — 19C BARDA Contract Value (Total contemplated payments, including recent increases)
• $79.1M — Product Delivery Revenue (9 Months 2025) (Recognized at a point in time)
• 71,611,302 — Common Shares Outstanding (Oct 24, 2025) (Slight increase from 71,404,669 at Dec 31, 2024)

Key Players & Entities

• SIGA Technologies, Inc. (company) — registrant
• U.S. Biomedical Advanced Research and Development Authority (regulator) — primary contract partner (BARDA)
• U.S. Strategic National Stockpile (company) — recipient of TPOXX deliveries
• U.S. Department of Defense (company) — customer for TPOXX sales
• Meridian (company) — counterparty for international sales in 2024
• $630 million (dollar_amount) — total contemplated payments under 19C BARDA Contract
• $14.3 million (dollar_amount) — increase in BARDA contract funding for manufacturing activities on April 8, 2025
• $13.2 million (dollar_amount) — increase in BARDA contract funding for pediatric formulation development on June 3, 2025
• $6,365,819 (dollar_amount) — net loss for the three months ended September 30, 2025
• $28,709,061 (dollar_amount) — net income for the nine months ended September 30, 2025

FAQ

Risk Factors

• Dependence on Government Contracts [high — regulatory]: The company's revenue is heavily reliant on government contracts, particularly the BARDA contract. Changes in government funding, priorities, or contract terms could significantly impact revenue and profitability. The 19C BARDA Contract contemplates up to approximately $630 million in payments, but its realization is subject to various conditions.
• Manufacturing and Supply Chain Disruptions [medium — operational]: Disruptions in manufacturing or the supply chain for key components could lead to delays in product delivery and impact revenue recognition. The company has received increases for manufacturing support under the BARDA contract, indicating ongoing operational focus.
• Quarterly Revenue Volatility [high — financial]: The company experienced a significant 73.8% decrease in total revenues for Q3 2025 ($2.62M) compared to Q3 2024 ($10.01M), driven by a sharp drop in product sales. This highlights the potential for substantial fluctuations in quarterly financial performance.
• Pediatric Formulation Development [medium — regulatory]: The company is undertaking pediatric formulation development under the BARDA contract, which involves specific regulatory and scientific challenges. Delays or failures in this development could impact future revenue streams and contract fulfillment.
• Accumulated Deficit [low — financial]: As of September 30, 2025, the company has an accumulated deficit of $37.64 million. While net income has grown for the nine-month period, the historical deficit indicates past periods of unprofitability.

Industry Context

SIGA Technologies operates in the biopharmaceutical sector, focusing on antiviral drugs. The market is characterized by long development cycles, high R&D costs, and significant reliance on government funding and partnerships for advanced development and procurement, particularly for countermeasures against potential biological threats.

Regulatory Implications

The company's operations are subject to stringent regulatory oversight by bodies like the FDA. Success in obtaining regulatory approvals and maintaining compliance with government contracts, such as those with BARDA, are critical. Changes in regulatory requirements or government priorities can significantly impact the business.

What Investors Should Do

1. Monitor BARDA Contract Milestones
2. Analyze Quarterly Revenue Trends
3. Evaluate Operating Expense Management
4. Assess Cash Burn and Dividend Policy

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $2.62M in total revenues, a 73.8% decrease from the prior year, and a net loss of $6.37M.
• 2025-09-30: End of Nine Months 2025 — Reported $90.78M in total revenues, a 58.6% increase from the prior year, and net income of $28.71M.
• 2025-09-30: Cash and Cash Equivalents Balance — Stood at $171.96M, an increase from the beginning of the period, despite significant dividend payments.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents were $155.40M. Total shares outstanding were 71,404,669.
• 2025-10-24: Common Shares Outstanding — Reported as 71,611,302, a slight increase from the end of the previous fiscal year.

Glossary

BARDA Contract

Biomedical Advanced Research and Development Authority contract, typically for the development and procurement of medical countermeasures. (SIGA's primary revenue driver, with the 19C contract potentially worth up to $630 million.)

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has historically incurred more expenses than revenues, with a deficit of $37.64M as of Sept 30, 2025.)

Deferred IV TPOXX revenue

Revenue recognized in future periods for goods or services that have been paid for but not yet delivered or rendered. (Represents a liability for future revenue recognition, totaling $10.24M as of Sept 30, 2025.)

Operating expenses

Costs incurred by a company in its normal business operations, excluding cost of goods sold. (Total operating expenses for Q3 2025 were $12.84M, exceeding revenues and contributing to the net loss.)

Benefit/(Provision) for income taxes

The amount of tax expense or benefit recognized in a period. A benefit reduces taxes, while a provision increases them. (The company recorded a significant tax benefit of $1.99M in Q3 2025 due to the net loss.)

Year-Over-Year Comparison

Compared to the prior year, SIGA Technologies experienced a dramatic 73.8% decrease in Q3 2025 revenue, leading to a net loss of $6.37M versus a net income of $1.34M in Q3 2024. However, for the nine-month period, revenue grew 58.6% to $90.78M and net income more than doubled to $28.71M. Cash reserves increased, but this was alongside a significant dividend payment. Operating expenses in Q3 2025 outpaced revenue, a reversal from the prior year's profitable quarter.

Filing Documents

• siga20250930_10q.htm (10-Q) — 815KB
• ex_851934.htm (EX-31.1) — 15KB
• ex_851935.htm (EX-31.2) — 15KB
• ex_851936.htm (EX-32.1) — 6KB
• ex_851937.htm (EX-32.2) — 6KB
• 0001437749-25-033636.txt ( ) — 5152KB
• siga-20250930.xsd (EX-101.SCH) — 53KB
• siga-20250930_cal.xml (EX-101.CAL) — 35KB
• siga-20250930_def.xml (EX-101.DEF) — 301KB
• siga-20250930_lab.xml (EX-101.LAB) — 282KB
• siga-20250930_pre.xml (EX-101.PRE) — 332KB
• siga20250930_10q_htm.xml (XML) — 898KB

-FINANCIAL INFORMATION

PART I-FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 2 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23

-OTHER INFORMATION

PART II-OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 26

SIGNATURES

SIGNATURES 27 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

- Condensed Consolidated Financial Statements

Item 1 - Condensed Consolidated Financial Statements SIGA TECHNOLOGIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, 2025 December 31, 2024 ASSETS Current assets Cash and cash equivalents $ 171,955,584 $ 155,400,262 Accounts receivable 2,490,234 21,166,129 Inventory 48,006,005 49,563,880 Prepaid expenses and other current assets 5,293,648 4,914,613 Total current assets 227,745,471 231,044,884 Property, plant and equipment, net 1,196,803 1,298,423 Deferred tax asset, net 1,560,453 10,854,702 Goodwill 898,334 898,334 Other assets 202,015 240,683 Total assets $ 231,603,076 $ 244,337,026 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 5,032,898 $ 1,340,337 Accrued expenses and other current liabilities 9,472,862 5,640,110 Deferred IV TPOXX revenue 10,240,000 10,330,800 Income tax payable 96,561 8,020,366 Total current liabilities 24,842,321 25,331,613 Other liabilities 3,281,879 3,200,650 Total liabilities 28,124,200 28,532,263 Commitments and contingencies Stockholders' equity Common stock ($ .0001 par value, 600,000,000 shares authorized, 71,611,302 and 71,404,669 , issued and outstanding at September 30, 2025 and December 31, 2024, respectively) 7,161 7,140 Additional paid-in capital 241,112,674 238,635,635 Accumulated deficit ( 37,640,959 ) ( 22,838,012 ) Total stockholders' equity 203,478,876 215,804,763 Total liabilities and stockholders' equity $ 231,603,076 $ 244,337,026 The accompanying notes are an integral part of these financial statements. 2 Table of Contents SIGA TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues Product sales and supportive services $ 889,748 $ 8,942,875 $ 85,835,855 $ 53,496,869 Research and development 1,730,252 1,066,906 4

View Full Filing

View this 10-Q filing on SEC EDGAR